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Abstract
Background: Insulin-like growth factor-I (IGF-I) provides pivotal cell survival and differentiation signals during inner ear
development throughout evolution. Homozygous mutations of human IGF1 cause syndromic sensorineural deafness,
decreased intrauterine and postnatal growth rates, and mental retardation. In the mouse, deficits in IGF-I result in profound
hearing loss associated with reduced survival, differentiation and maturation of auditory neurons. Nevertheless, little is
known about the molecular basis of IGF-I activity in hearing and deafness.
Methodology/Principal Findings: A combination of quantitative RT-PCR, subcellular fractionation and Western blotting, along
with in situ hybridization studies show IGF-I and its high affinity receptor to be strongly expressed in the embryonic and postnatal
mouse cochlea. The expression of both proteins decreases after birth and in the cochlea of E18.5 embryonic Igf12/2 null mice,
the balance of the main IGF related signalling pathways is altered, with lower activation of Akt and ERK1/2 and stronger
activation of p38 kinase. By comparing the Igf12/2 and Igf1+/+ transcriptomes in E18.5 mouse cochleae using RNA microchips and
validating their results, we demonstrate the up-regulation of the FoxM1 transcription factor and the misexpression of the neural
progenitor transcription factors Six6 and Mash1 associated with the loss of IGF-I. Parallel, in silico promoter analysis of the genes
modulated in conjunction with the loss of IGF-I revealed the possible involvement of MEF2 in cochlear development. E18.5 Igf1+/+
mouse auditory ganglion neurons showed intense MEF2A and MEF2D nuclear staining and MEF2A was also evident in the organ
of Corti. At P15, MEF2A and MEF2D expression were shown in neurons and sensory cells. In the absence of IGF-I, nuclear levels of
MEF2 were diminished, indicating less transcriptional MEF2 activity. By contrast, there was an increase in the nuclear
accumulation of FoxM1 and a corresponding decrease in the nuclear cyclin-dependent kinase inhibitor p27Kip1.
Conclusions/Significance: We have defined the spatiotemporal expression of elements involved in IGF signalling during
inner ear development and reveal novel regulatory mechanisms that are modulated by IGF-I in promoting sensory cell and
neural survival and differentiation. These data will help us to understand the molecular bases of human sensorineural
deafness associated to deficits in IGF-I.
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Introduction
Insulin-like growth factor I (IGF-I) is a member of the insulin
family that regulates development and tissue homeostasis [1,2]. It
acts primarily by binding with high affinity to the IGF-I tyrosine
kinase receptor (IGF1R) and its activity is modulated by IGF-binding
proteins (IGFBP) [3]. IGF factors, receptors and binding proteins
form the IGF system. Peak expression of IGF-I in the nervous system
occurs during late embryonic and neonatal periods, although
relatively high expression is maintained in areas of high plasticity,
such as the olfactory bulb and hippocampus [4]. Mutations in mice
have shown that IGF-I modulates survival, proliferation and
differentiation of all the neural lineages studied, and it promotes
synaptogenesis and dendritic arborisation in projection neurons
[4,5]. Activation of the IGF1R leads to phosphorylation of insulin-
receptor-substrates and activation of the cytosolic serine-threonine
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MAP kinases and Akt kinases that induce the translocation of
transcription factors to the cell nucleus, thereby initiating specific
gene expression programmes [6,7]. Deficits in IGF-I are associated
with severe nervous system disorders, including neurodegenerative
diseases, and treatment with IGF-I promotes neural cell repair and
regeneration [8]. Homozygous mutations in human IGF1 result in a
wide range of disorders including intrauterine growth retardation,
postnatal growth failure, microcephaly and mental retardation. They
also cause severe bilateral sensorineural deafness (ORPHA73272;
http://www.orpha.net; [9,10,11]).
Normal development of the inner ear depends on IGF-I
signalling [12]. The auditory sensory epithelium is the organ of
Corti, which is composed of linear rows of hair cells and
supporting cells housed within the cochlea. The mouse inner ear
develops from embryonic day (E)8 from the otic placode, a patch
of ectoderm that invaginates and pinches off to form the otic
vesicle from which all the sensory epithelial cells and sensory
neurons are derived. By E15.5, the organ of Corti has acquired its
full complement of cell types although it does not become
functionally mature until the onset of hearing at postnatal day 12–
14 [13]. Igf1 null (Igf12/2) mice are dwarfs that present organ-
specific growth retardation and a 30% reduction in brain size. The
impact on the nervous system includes loss of selective neuronal
populations, hypomyelinization and reduced peripheral conduc-
tion velocities [14,15]. As in man, IGF-I deficit in the mouse
causes all-frequency bilateral sensorineural hearing loss and a
delayed response to acoustic stimuli [16]. From postnatal day P5
cochlear development is severely impaired in mutant Igf12/2
mice, which develop a smaller cochlea with an immature tectorial
membrane. In addition, these animals suffer aberrant synapto-
genesis, abnormal innervation of the sensory hair cells in the organ
of Corti, poor myelination and a significant decrease in the
number and size of auditory neurons [17,18]. The marked
reduction reported in neural cell number at P20 is due to increased
apoptotic cell death of both neurons and Schwann cells [17].
Here, we have explored the otic-specific targets of IGF-I
signalling to further understand the function of this factor in the
inner ear and how its deficit causes neurosensorial deafness.
Comparative gene expression profiles from the cochlea of wild-
type (Igf1+/+) and Igf12/2 mice at embryonic day E18.5 suggest
that IGF-I modulates sensory cell differentiation and neural cell
fate decisions during late otic development. The expression
patterns of Six6, Mash1 and Fgf15 are altered in the cochleae of
Igf12/2 mice. Changes also occur in the expression, protein levels
and nuclear localization of FoxM1, a forkhead box transcription
factor that is ubiquitously expressed in proliferating cells and one
of its targets the cyclin-dependent kinase inhibitor p27Kip. In silico
analysis of the promoter regions of differentially expressed genes
selected from the microarray analysis of null versus wild type
cochleae at E18.5, pointed to the transcription factor myocyte
enhancing factor 2 (MEF2) as a novel downstream target of
cochlear IGF-I signalling. The nuclear expression of MEF2A and
D was lower in the absence of IGF-I. Thus, for the first time we
show that MEF2 and FoxM1 activities are modulated by IGF-I in
the mouse cochlea. These results also provide novel clues to the
molecular mechanisms underlying otic development and the
causes of neurosensorial deafness associated with defects in IGF-I.
Materials and Methods
Mouse Handling and Genotyping
Heterozygous mice in which the Igf1 gene underwent targeted
disruption were bred, maintained and genotyped as described
[14,17]. In brief, E18.5 Igf12/2 embryos on a C57BL/6J genetic
background, which die at birth, were used for the DNA array study,
whereas a hybrid MF1/129/sv genetic background was used to
increase survival in the resultant null mice as described [14,17].
Adult survival was around 20% of the newborn null Igf12/2 mice.
Both mouse strains showed similar cochlear gene and protein
expression profiles when tested at E15.5 and E18.5. Mouse
genotypes were identified using the REDExtract-N-AmpTMTissue
PCR Kit (XNAT, Sigma) following the manufacturer’s instructions
and with the following primer sets specific for the Igf1 and
neomycin genes (Igf1 forward 59-GTCTAACACCAGCC-
CATTCTGATT-39; Igf1 reverse 59-GACTCGATTTCACC-
CACTC-GATCG-39; neomycin forward 59-GCTTGGGTGGA-
GAGGCTAT-CC-39; and neomycin reverse 59-CCAGC-
TCTTCAGCAATATCACGGG-39). Hearing was tested in adult
animals by recording auditory brainstem responses as described
[16] (results not shown). Animals were humanely sacrificed and all
procedures were in accordance with the European Council
Directive (86/609/EEC) and the Bioethics Committee of the
CSIC.
Transcriptome Analysis by GeneChip Arrays
E18.5 was selected because most Igf12/2 mice die in early
postnatal development. E18.5 cochleae from two Igf1+/+ and two
Igf12/2 embryos were dissected and pooled to obtain RNA. Three
independent RNA pools of each genotype (6 mice) were isolated
with Trizol (Invitrogen) following the manufacturer’s instructions.
The purity of RNA was assessed with an Agilent Bioanalyzer 2100
(Agilent Technologies). Six additional microarrays were hybridized
with whole lung RNA obtained from the same mice or their siblings
and were included in the analysis to compare the expression profiles
of different organs (GSE17157; JGP manuscript in preparation).
Cochlear complementary RNA (cRNA) for hybridization to
MOE430A GenechipsH (Affymetrix) was prepared by sequentially
generating cDNA with the one-Cycle cDNA Synthesis Kit, which
was purified and used as a template in the in vitro transcription
reaction for cRNA amplification and biotin labelling. The cRNA
was then hybridized to the GeneChipH arrays and scanned with a
GeneChipH Scanner 3000 7G 4C (Affymetrix).
An initial analysis was performed with MAS5.0 (Affymetrix) and
Robust Multiarray Average (RMA) software [19], which indicated
a very high variability that was associated with the biological
variability and non-specific hybridization. Because most of the
tissue-specific genes are expressed at low levels at this developmen-
tal stage, the high background signal of common genes generated a
very high noise-to-signal ratio. The software package PUMA
(Propagating Uncertainty in Microarray Analysis) was then used to
estimate the gene expression levels. This package, integrated in the
Bioconductor project (http://www.bioconductor.org), uses novel
probabilistic models to analyse affymetrix GeneChip array data.
Specifically, the multi-mgMOS (multi-chip modified gamma model
for oligonucleotide signal) model was used to extract gene
expression levels and their estimated uncertainties [20]. The
analysis of the Fold change (FC) was used in combination with
the Probability of Positive Log Ratio (PPLR) algorithm from the
PUMA package, to reduce the number of false positives [21]. PPLR
associates probability values (between 0 and 1) to each log ratio,
which represents the probability of the log Ratio being positive.
This probability is a measure of the false positive detection of
differential expression and it allows the selected Differentially
Expressed (DE) genes to be ranked in order of the robustness of the
prediction. We defined DE genes in Igf1+/+ mice as those that
presented a positive FC greater than one log2 unit with an
associated probability higher than 0.95. Conversely, in Igf12/2
IGF-I in Cochlear Development
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mice we defined DE genes as those that presented a negative FC
less than -1 with an associated probability lower than 0.05.
Genes were classified by their ontology and by the biological
processes in which they are implicated using the PANTHER
Classifications Systems software (http://www.pantherdb.org) and
FATIGO+ (http://babelomics.bioinfo.cipf.es/).
Transcription Factor Analysis
The promoter regions of up-regulated genes in the Igf12/2
mouse cochlea selected either by their DE ranking and/or their
association with sensorial deficits in humans (IL-13ra1, Fgf15,
Foxm1, Six6, Rorb, Rp1h and Ush1c), were compared using the
MEME software (http://meme.sdsc.edu/meme/intro.html) to
identify common motifs. The promoter regions were selected
using the PromoSer database (http://biowulf.bu.edu/zlab/
PromoSer/) extracting 1.5 Kb upstream and 50 bp downstream
of the Transcription Start Site (TSS). Only motifs with a pair-wise
correlation lower than 0.30 were selected and the selected motifs
were searched for known transcription factor binding sites using
TESS (http://www.cbil.upenn.edu/cgi-bin/tess/). Only the tran-
scription factors sites with the highest Log-likelihood score were
selected. Similarly, down-regulated genes with a FC.1 were
grouped and the common motifs in the promoter region were
analysed using either the method indicated above or the
FATIGO+ software with similar results.
Low Density Arrays and Quantitative RT-PCR
TaqManH Low Density Arrays containing three replica probes
for each of the twenty genes selected from the array data were
hybridized with cDNA generated by reverse transcription (High
Capacity cDNA Reverse Transcription Kit. Applied Biosystems).
cDNA was prepared from three to five different RNA pools
corresponding to six to ten mice for each genotype. Each RNA pool
was isolated as described above from the pooled cochleae from two
embryos or mice for each genotype taken at the following times:
E15.5, E18.5, P5, P15, P30, P60 and P90. PCR was performed on
an Applied Biosystems 7900HT Fast Real-Time PCR System and
the genes were selected on the basis of their FC, physiological
interest and the availability of appropriate TaqManH probes. In
addition, probes to test the temporal expression of the IGF system
factors, receptors and transport proteins were used. Eukaryotic 18S
rRNA was chosen as an endogenous housekeeping control gene and
the estimated gene expression was calculated as 22DCt, multiplying
this value by a factor of 106 to generate a clearer graphical
representation. Alternatively, gene expression was analyzed by real
time PCR using validated probes from TaqManH Gene Expres-
sion Assays (https://products.appliedbiosystems.com/ab/en/US/
adirect/ab?cmd=ABGEKeywordSearch; Applied Biosystems).
Probes used are listed in Table S1 and included those for Igf2,
Irs2, Foxm1, Foxg1, Mash1, Mef2a, Mef2c and Mef2d. Assays were done
following manufacture’s instructions and using as reference the
expression levels of 18S. The relative quantification values (RQ)
were calculated by the 22DDCt method and data are presented as
means of log10RQ.
In Situ Hybridization
In situ hybridization was performed essentially as described
previously [22], with minor modifications. The cDNA used to
generate the in situ hybridization probes are detailed in Table S2
Three E15.5, E18.5 and P5 mice per genotype were tested in
parallel in three independent experiments. No signal was obtained
with the control sense probes (data not shown). Sections were
incubated overnight at 70uC with 1 mg/ml of the digoxigenin-
labeled probes, and binding detected by overnight incubation with
alkaline phosphatase-conjugated anti-digoxigenin antibody
(1:3500, Roche), which was visualised with NBT (Nitro blue
tetrazolium chloride)/BCIP (5-Bromo-4-chloro-3-indolyl phos-
phate, toluidine salt; 1:50, Roche) or Fast Red (Roche) for
fluorescence.
Cochlear Morphology and Immunohistochemistry
Selected E15.5, E18.5, P5 and P15 cochlear sections were
examined by dual in situ hybridization and immunohistochemistry
as described in [23] using the primary antibodies summarized in
Table S3. Sections were then sequentially covered with the
secondary antibody solution (1:100, biotin-conjugated anti-mouse
IgG or biotin-conjugated anti-rabbit, Chemicon), and extravidin
peroxidase (1:200, Sigma). Finally, antibody binding was visualised
using DAB as the chromogen and the sections mounted in Mowiol
for observation under a Nikon 90i microscope. When indicated,
Alexa Fluor 488 goat anti-rabbit, Alexa Fluor 546 goat anti-rabbit,
Alexa goat anti-mouse 488 or Alexa donkey anti-goat 488 dyes
(1:400, Molecular Probes) were used as the secondary antibody.
Three embryos or mice per genotype were tested in parallel in three
independent experiments. Control experiments without primary
antibody were carried out for each reaction and indicated that the
staining pattern was specific for antigen recognition (data not
shown).
Cochlear Protein Extraction and Analysis
Frozen cochleae from E15.5, E18.5, P5, P15, P60 and P90 mice
were pooled and homogenized in 200 ml of ice-cold RIPA lysis
buffer containing 0.01% of the P8340 protease and P5726
phosphatase inhibitor cocktails (Sigma) and heated to 95uC for
5 min. Cochlear extracts were cleared by centrifugation at 11,800
rpm for 5 min at 4uC, and the supernatant was stored at 270uC
until use. Three to six different pools from each genotype were
used. When indicated, NE-PERH Nuclear and Cytoplasmic
Extraction Reagent (PIERCE Biothecnology) was used to prepare
the cytoplasmic and nuclear extracts from E18.5 and P15 cochleae
as indicated by the manufacturers. The protein content of the
samples was determined with the CoomassieH Plus Protein Assay
Reagent Kit or Micro BCA Protein Assay Kit (PIERCE
Biothecnology) using BSA as the standard.
Equal amounts of cochlear protein were subjected to SDS-
PAGE on 8%, 10% or 15% polyacrylamide gels and the proteins
were then transferred to PVDF membranes in a Bio-Rad Trans
Blot apparatus according to the manufacturer’s instructions. After
incubation with a blocking solution, the membranes were probed
overnight at 4uC with the appropriate primary antibodies
summarized in Table S3. All antibodies were diluted in blocking
solution except those against Akt, P44/42 ERK and p38 MAPK,
which were diluted in TBS-T containing 5% BSA. The
membranes were then washed and incubated with the appropriate
peroxidase conjugated secondary antibodies for 1 h at RT.
Immunoreactive bands were visualized by ECL (GE Healthcare
Amersham) and the bands were quantified by densitometry with
NIH Image J software. Statistical significance was estimated by
Student’s t-test after using Levene’s test to confirm the equality of
variances.
Results
Spatiotemporal Pattern of Expression of the IGF System
Elements and Modulation of Target Kinase Activities in
the Igf12/2 Null Mouse
Previous studies have shown that cochlear structures are positive
for IGF-I immunostaining, which was observed in the stria
IGF-I in Cochlear Development
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vascularis, spiral limbus and sensory supporting cells, as well as in
subpopulations of auditory ganglion neurons at postnatal day P20
[17]. However, because IGF-I is a hormone secreted by the liver, it
was important to determine whether or not it was synthesised in
the cochlea. To address this question we performed in situ
hybridization for Igf1 and Igf1r at stages E15.5, E18.5 and P5
(Fig. 1).
At stages E15.5 and E18.5, the auditory epithelium can be
divided into the greater epithelial ridge (GER), which includes the
single row of inner hair cells, and the lesser epithelial ridge (LER),
which includes the three rows of outer hair cells (Fig. 1A–B). By P5
(Fig. 1C), the structure of the organ of Corti more closely
resembles that of the adult. Igf1 and Igf1r temporal expression
patterns are shown in Fig. 1A–C painted in blue and red tones,
respectively. At E15.5, Igf1 mRNA was strongly expressed in an
area corresponding to the future stria vascularis and more weakly
in those areas that will give rise to Reissner’s membrane, the spiral
limbus and the outer sulcus (Fig. 1D,G). The expression of Prox1
was used to define the LER (see Fig. 1M; [24]). At E18.5, Igf1 was
still expressed strongly in the stria vascularis and spiral limbus,
while it was relatively weak in the outer sulcus and Reissner’s
membrane (Fig. 1E,H). The expression of Igf1 was restricted by
P5, when it was detected in the marginal cells of the stria vascularis
and it overlapped with the cells expressing the Kir4.1 potassium
channel (Fig. 1F,I,I’). Weaker expression was observed in the inner
and outer sulcus.
Igf1r was ubiquitously expressed at E15.5 but it was stronger in
the GER, LER and auditory ganglion (Fig. 1J,M). The expression
pattern remained similar at E18.5 (Fig. 1K,N), although it was
notably stronger in the apical turn of the auditory ganglion
(Fig. 1K’). As with Igf1, the expression of Igf1r was more restricted
by stage P5 and interestingly, the pattern was complementary to
that of Igf1 with this receptor being confined to the inner spiral
sulcus, Hensen’s, Claudius cells and the basal cells of the stria
vascularis (Fig. 1L,O,O’). The pattern of expression of the Igf1r did
not show any change in the Igf12/2 null mouse cochlea with
respect to the wild type cochlea at the stages studied (E15.5, E18.5,
P5 and P15; Fig. S1).
The temporal expression profiles of several genes of the IGF
system were studied in the cochleae of Igf1+/+ and Igf12/2 mice by
qRT-PCR. These included Igf1, Igf1r, Ins2, Igf2, Igfbp2 and Igfbp3
at stages E15.5, E18.5, P5, P15, P30, P60 and P90. In Igf1+/+ mice
the expression of Igf1 remained high during development, despite
the modest postnatal decrease, while as expected it was absent in
the Igf12/2 cochlea (Fig. 2A). Ins2 was not detected in wild type or
mutant mice, at any of the time points studied (data not shown). In
contrast, Igf2 expression remained high during development and
dropped after birth, the expression levels of Igf2 did not show
statistically significant differences between wild type and mutant
mice at any of the time points studied (data not shown). Expression
of Igf1r in the Igf1+/+ cochlea decreased dramatically from E15.5 to
P5, and it increased with age thereafter (Fig. 2B). In the Igf12/2
cochlea, Igf1r was expressed at higher levels than normal after
birth and it remained proportionally higher throughout the period
studied (Fig. 2B). IGFBP expression has been reported in the
cochleae of several species [25,26]. High levels of Igfbp2 and Igfbp3
expression were detected at E15.5, although this expression
diminished rapidly thereafter. There was slightly higher expression
of these binding proteins in the cochleae of Igf12/2 null mice
(Fig. 2C–D).
Upon IGF-I binding, its high affinity receptor IGF1R tyrosine
kinase activity is turned on and autophosphorylates receptor
residues that act as docking sites for adaptor proteins like the
insulin receptor substrate 2 (IRS2) [27], which in turn will activate
downstream signalling pathways. Fig. 2E and Fig. S2 show that
IGF1R is less phosphorylated in the Igf12/2 null mouse cochlea
than in the wild type. Interestingly, there was a slight (30%
p,0.05) increase in the tyrosine phosphorylation ratio of the
IGF1R in the Igf12/2 from E18.5 to P90 when compared with the
relative tyrosine phosphorylation ratio observed at E15.5; no
changes could be shown for IRS2 levels at the times studied
(Fig. 2F and S2).
IGF-I signalling is mediated by a network of intracellular
mediators that include the phosphatidylinositol-3-kinase/Akt
pathway and the mitogen-activated kinase cascades. In the
E18.5 Igf12/2 null mouse cochlea there were reductions in the
relative levels of activated phospho-AktSer473 (31%, p,0.01) and
phospho-ERK1/2 (56%, p,0.05), whereas phospho-p38 MAPK
was strongly activated (261%, p,0.005) when compared with the
Igf1+/+ wild type mouse cochlea (Fig. 2E,G). Akt and ERK1/2
MAPK activation are essential for cell survival and proliferation,
whereas p38 MAPK forms part of the cellular response to
environmental stress, such as ultraviolet light, heat, osmotic shock
and inflammatory cytokines [28]. These data indicate that the
IGF-I deficit at E18.5 diminishes the activity of the pathways that
control cell proliferation and survival, whilst those involved in the
cellular response to stress are heightened.
To recap, the main elements of the IGF system are present
during the development of the cochlea and they are expressed in
specific spatiotemporal patterns. IGF-I deficit affects the expres-
sion levels of the IGF system elements, and key IGF-I-activated
signalling pathways are profoundly altered. These data, together
with the reported morphological alterations and the profound
sensorineural deafness that the deficit in IGF-I causes in mice and
humans, prompted us to further study the molecular mechanisms
underlying IGF-I activity in the developing mouse cochlea.
Identification of Differentially-Expressed Genes in the
E18.5 Igf12/2 Mouse Cochlea
To study the otic-specific gene targets of IGF-I, mRNA from
whole cochleae of E18.5 Igf1+/+ and Igf12/2 mice was hybridized
with mouse ‘whole genome’ arrays (MOE430A) from Affymetrix.
The results were submitted to the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) with the accession number
GSE11821.
We used multi-mgMOS and the model developed by the
PUMA group to estimate gene expression levels with credibility
intervals that quantify the measured variance associated with the
estimated target concentration within a sample. This within-
sample variance is a significant source of uncertainty in
oligonucleotide arrays, especially for genes expressed at low levels.
Final targets were selected using the PPLR algorithm that reduces
the number of false positives. Genes that presented a Fold Change
higher than a log2 unit of 1 (FC,1 with P,0.05 and FC.1 with
P.0.95) were selected for further analysis. Following these criteria,
the expression of 167 genes was seen to be considerably lower and
64 genes were expressed more strongly in the absence of IGF-I.
These genes were then compared with the NCBI Mus musculus
gene database, and ordered by gene ontology and biological
processes with the programs PANTHER and FATIGO+. This
analysis identified the different biological processes and cellular
activities of the cochlear genes affected by IGF-I deficit (Fig. S3). A
further selection was carried out on the basis of biological function,
reported expression in the inner ear or association with human
deafness, as well as for technical parameters as the FC and the low-
variance between arrays. Table S4 shows selected genes
differentially expressed in the absence of IGF-I, which include
genes related to sensorial defects (Ush1c, Esrrb and Tub), ion
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Figure 1. Igf1 and Igf1r mRNA expression in the cochlea. (A–C) Cartoons of the organ of Corti at E15.5, E18.5 and P5 show the expression of
Igf1 (blue), Igf1r (orange and red) or both (purple). (D–O) In situ hybridization of Igf1 (D-I,I’) and Igf1r (J-O, O’) in normal embryos at E15.5 (D,G,J,M),
E18.5 (E,H,K,N) and in P5 mice (F,I,L,O). Dual immunostaining with anti-Kir4.1 was performed to identify the neural projections, the stria vascularis and
pillar cells (F,I,I’) and with anti-Prox1 to identify the pillar cells, Deiter’s cells, and auditory neurons (J–O,O’). (D-I) Igf1 expression was located in the
stria vascularis (long black arrows), spiral limbus (black arrowheads), outer sulcus (green arrowheads) and Reissner’s membrane (short black arrow). At
P5 the Igf1 expression in the stria vascularis was observed in the marginal cells (I’). (J,K,M,N) At E15.5 and E18.5, Igf1r was strongly expressed in the
GER (red arrow) and weakly in the LER (red arrowhead). (L,O) At P5, Igf1r expression presented a complementary pattern to that of Igf1 and was
observed within the inner spiral sulcus (red arrows), Claudius and Hensen’s cells (red arrowheads). Igf1r was also located in the AG (asterisk in J,K, K’)
and in the basal cells of the stria vascularis (O’). Three embryos per genotype were tested in parallel in three independent experiments. GER, greater
epithelial ridge; IHC, inner hair cells; LER, lesser epithelial ridge; OHC, outer hair cells; PC, pillar cells; AG, auditory ganglion; SM, scale media; ST, scala
tympani; SV, scala vestibuli; TM, tectorial membrane. Scale Bars: D,E,F, 150 mm (D,E,F,J,K,L); A,B,C, 50 mm; G,H,I, 50 mm (G,H,I,M,N,O); I’, 10 mm; O’,
20 mm and K’, 30 mm.
doi:10.1371/journal.pone.0008699.g001
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transporters (Cacna1f, Kcnd2, Kcnmb1 and Mlc1), the acetylcholine
transporters Slc18a3 and Slc5a7 and the strial functional modula-
tors Esrrb and Cldn18, among others that have been previously
reported as cochlear-expressed genes.
To assess the organ specificity of the IGF-I target genes
identified in this study, a parallel study was carried out on total
RNA obtained from the lungs of Igf12/2 and wild type littermates
(GSE17157; JGP, manuscript in preparation). The comparison of
the differentially expressed genes obtained from both studies
indicated that 94 genes were up-regulated in the lung, whereas
only 64 genes were up-regulated in the cochlea. Interestingly none
of these genes was common to the two tissues. In addition, 56 lung
genes were down-regulated in the Igf12/2 mouse, in striking
contrast to the weaker expression of 167 cochlear genes when
compared to that in the wild type mouse cochlea. Only 3 genes
were present in both databases: integrin alpha V (Itgav), solute
carrier family 4 member 1 (anion exchanger - Slc4a1) and the
ubiquitin specific peptidase 12 (Usp12).
Figure 2. Time-course of mRNA expression of IGF-system genes and the activation levels of signalling mediators in the E18.8
cochlea. (A–D) mRNA expression levels of Igf1, Igf1r, Igfbp2 and Igfbp3 were analyzed by qRT-PCR in Igf1+/+ (open circles) and Igf12/2 (closed circles)
mice at E15.5 and E18.5 (n = 8), P5, P15, P30, P60 and P90 (n = 6). Eukaryotic 18S rRNA was used as the endogenous housekeeping control gene. The
estimated gene expression was calculated as 22DCt?106. (A) Igf1 expression was high in normal cochlea and absent in the null mice. (B) Igf1r
expression in normal cochleae decreased dramatically from E15.5 to P5 and increased with age thereafter. In the Igf12/2 cochlea, Igf1r followed the
same pattern but consistently presented higher levels at all time points studied. Igfbp2 (C) and Igfbp3 (D) mRNA levels were high at E15.5 but they
dropped thereafter. Their profiles were slightly higher in the Igf12/2 cochlea. (E) IGF-I modulates IGF1R, ERK, Akt and p38 activation at E18.5. (F)
Levels of phosphorylated-IGF1R and IRS2 in cochlear protein extracts from Igf1+/+ and Igf12/2 mice were studied by Western blotting at E15.5, E18.5,
P5, P60 and P90. Data are presented as percentage of Igf12/2 null mouse protein levels compared to the Igf1+/+. (G) To determine the levels of
phosphorylated AktSer473, ERK and p38 MAPK, cochlear protein extracts from E18.5 Igf1+/+ and Igf12/2 mice were analysed by immunoblotting.
Membranes were re-probed with b-Actin as a loading control, and for the non-phosphorylated forms of AKT and ERK1/2. Films were scanned,
densitometry performed by using ImageJ software and the levels were normalised by giving a value of 100 to the Igf1+/+ mouse samples. Values are
presented as mean6SEM of at least 3 different experiments involving at least 6 mice per condition for Akt, ERK and p38 MAPK. The statistical
significance estimated by Student’s t-test was as follows ***p,0.005; **p,0.01; *p,0.05.
doi:10.1371/journal.pone.0008699.g002
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The changes in the expression of 15 genes were confirmed by
qRT-PCR using TaqMan probes where available, or by in situ
hybridization. qRT-PCR has proven to be an efficient method to
verify DNA array results and the predicted differences were
confirmed for 68% of the genes studied (see Table S3). At E18.5,
qRT-PCR of total cochlear mRNA confirmed that Akr1c13, Fgf15,
Foxm1, Mash1, Rp1h, Six6 and Ush1c transcripts were more strongly
expressed in the cochleae of Igf12/2 mice [29,30,31,32]. In
contrast, Foxg1, which is involved in the morphogenesis of the
mammalian inner ear [33], did not present a differential
expression in the null mice (see Table S3).
These data contribute to our understanding of the molecular
basis of the delayed maturation of the sensory epithelium reported
in IGF-I deficit [17], extending the actions of this factor and
highlighting a relationship with the Usher’ syndrome molecules
Ush1c [32], Rp1h [34] and Tub [35] whose mutations cause both
deafness and blindness in men (ORPHA120433, ORPHA886).
Parallel in situ hybridization studies confirmed the aberrant
cellular expression of Six6 and Mash1, and of the fibroblast growth
factor Fgf15. These genes were expressed in the Igf12/2 cochlea
despite being absent or expressed at very low levels in the Igf1+/+
cochlea. Within the central nervous system, Six6 is expressed in the
presumptive and differentiating neural retina, ventral optic stalk,
olfactory placodes, hypothalamus, and pituitary gland [36].
Although Six6 mRNA is not normally expressed in the auditory
nerve at E18.5 (Fig. 3A,B), transcripts were clearly detected in the
Figure 3. Up-regulation of Six6, Mash1 and Fgf15 in the embryonic cochlea of the Igf12/2mouse. In situ hybridization for Six6 (A, B, D, E),
Mash1 (C, F) Fgf15 (G–J and N–Q), Fgf8 (K) and FgfR3 (L) transcripts was performed on cryostat sections from Igf1+/+ and Igf12/2 E18.5 (A–F and G–
M) and P5 (N–Q) cochleas. (M) Schematic drawing of the organ of Corti showing the different cell types at E18.5. Six6 and Mash1 expression was
higher in the auditory nerve (AN) of E18.5 Igf12/2 cochlea. Fgf15 mRNA expression located in the border cells (BC) and in the inner phalangeal cells
(IPC) of E18.5 Igf12/2 mice (arrows in I,J), was absent in Igf1+/+ mice (G,H). Fgf8 (blue arrowhead in K) expression was detected in IHC in Igf12/2 and
FgfR3 (blue staining in L) transcripts were also detected in Igf12/2 supporting cells. At P5, Fgf15 expression was observed in the IPC and BC in the
basal turn of the cochlea of both Igf12/2 (arrows in N,O,O’,P) and normal (arrowhead in Q) mice. Immunostaining for Prox1 (brown in A,B,D,E),
MyosinVIIa (brown in H,P green in I,L,O) and p75 (brown in G,J,K) identified supporting cells, inner and outer hair cells and pillar cells respectively.
Three embryos per genotype were tested in parallel in three independent experiments. DC, Deiter’s cells; HC, hair cells; IHC, inner hair cells; OHC,
outer hair cells; PC, pillar cells; SM, scala media; ST, scala tympani; SV, scala vestibuli; TM, tectorial membrane. Scale Bars: A, 100 mm (A,D,N); E, 100 mm
(B, C, E, F); 50 mm (G); I, 20 mm (I,O,O’); and 30 mm (H,J,K,L,P,Q); M, 10 mm.
doi:10.1371/journal.pone.0008699.g003
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Igf12/2 mouse (Fig. 3D,E, arrows in E). The proneural bHLH
transcription factor Mash1 was also more strongly expressed in the
auditory nerve (AN) of the E18.5 Igf12/2 mouse (Fig. 3C,F),
overlapping the glial transition zone [37]. At P5, Mash1 expression
was similar between genotypes and was associated with neuronal
bodies amongst fibres that were strongly labelled for myelin basic
protein, which may suggest that at this stage Mash1 positive cells
are root neurones [38] (Fig. S4). These results suggest that IGF-I
participates in late neural cell fate decisions in the auditory
ganglia.
Fibroblast growth factors and their receptors have key roles
during inner ear development [39,40]. At E15.5 and E18.5, Fgf15
is not normally expressed in the organ of Corti of wild type mice
but transcripts from this gene were found in the inner phalangeal
cells and border cells of the Igf12/2 mice at E16.5 and E18.5, close
to the inner hair cells in the basal turn of the cochlea (data not
shown and Fig. 3G,J). These transcripts were associated with the
specific markers p75 for pillar cells and myoVIIa for hair cells
(Fig. 3I,J, see reference cartoon in M). At P5, Fgf15 expression in
the border and inner phalangeal cells was very similar between
genotypes (Fig. 3N–Q). Expression of Fgf8 (Fig. 3K) and Fgfr3
(Fig. 3L) was unchanged in the Igf12/2 cochlea at E18.5.
The expression profiles of Akr1c13, Dnabj7, Fgf15, Fibp, Foxg1,
Foxm1, Kcnd2, Kif17, Mash1, Shbg, Retnla, Rp1h, Six6, Slc19a2 and
Ush1c at stages E15.5, E18.5, P5, P15, P30, P60 and P90 were
studied in the cochleas of Igf1+/+ and Igf12/2 mice by qRT-PCR.
They were categorised in three groups: i) genes with profiles that
differed during embryonic development, either increasing like
Akr1c13, Fgf15, Foxm1 and Six6 (Fig. 4A) or decreasing like Dnabj7
(Fig. 4B), in the Igf12/2 cochlea; ii) genes with profiles that differed
during the postnatal stages, increasing like Fibp, Shbg (Fig. 4C),
Slc19a2 and Rp1h or decreasing like Kif17 and Retnla (Fig. 4D) in
the Igf12/2 cochlea; iii) genes that were affected by the absence of
Igf12/2 throughout embryonic and postnatal development, such
as Mash1, Ush1c (Fig. 4E) and Kcnd2 (Fig. 4F). One example from
each category is shown (Fig. 4).
FoxM1 and MEF2 Levels and Intracellular Localization Are
Differentially Regulated in the Igf12/2 Mouse Cochlea
In the mouse embryo, FoxM1 is associated with cell cycle control
and DNA repair in neural progenitors and its expression decreases
after differentiation [41]. FoxM1 prevents nuclear localization of
the cyclin-dependent kinase inhibitor p27Kip1 and is essential for
cytokinesis [42,43]. In the E18.5 Igf12/2 mouse cochlea, Foxm1
expression levels were up-regulated (+1.7 fold log2 change using
Genechip Arrays and +1.2 with qRT-PCR) with respect to the wild
type. To further explore the possible functional consequences of this
altered Foxm1 expression, cytoplasmic and nuclear protein extracts
from the whole cochlea of E18.5 and P15 mice were analyzed. At
E18.5, nuclear FoxM1 protein levels were 154% higher (p,0.05) in
Figure 4. Time-course of IGF-I target gene mRNA expression. qRT-PCR analysis of mRNA from Igf1+/+ (open circles) and Igf12/2 (closed circles)
cochleae obtained at E15.5, E18.5, P5, P15, P30, P60 and P90. Eukaryotic 18S rRNA was used as the endogenous housekeeping control gene.
Estimated gene expression levels are represented as 22DCt?106. Fgf15 (A) and Dnabj7 (B) expression profiles were similar, with high levels at E15.5 and
lower levels from E18.5 onwards. Up to P5, more Fgf15 transcripts and fewer Dnabj7 transcripts were detected in the mutant cochlea. Shbg levels
were higher from P5 onwards (C) whilst Retnla (D) expression increased with age. Although weaker in the Igf12/2 cochlea, Ush1c (E) mRNA levels
were higher in the Igf12/2 cochlea and Kcnd2 levels were lower from P15 onwards (F). Statistical significance estimated by Student’s t-test was as
follows ***p,0.005; **p,0.01; *p,0.05, with respect to wild type mice data (n = 6 mice/genotype).
doi:10.1371/journal.pone.0008699.g004
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Igf2/2 mice, whilst the cytoplasmic component was 57% lower
(p,0.005, Fig. 5A,B). In contrast, at P15, FoxM1 protein levels
were only 13% higher in the nuclear extract of whole cochlea,
whilst the cytoplasmic fraction was 50% lower (p,0.05, Fig. 5B)
Cytoplasmic protein levels for p27Kip1 were 121% higher (p,0.05)
in Igf2/2 mice at E18.5 whilst the nuclear fraction was 27% lower
(p,0.05) (Fig. 5B). At P15, p27Kip1 cytoplasmic levels were 24%
higher in the Igf12/2 mouse and the nuclear fraction was 58%
lower. These differences in subcellular localization of both FoxM1
and p27Kip1 in the Igf12/2 mouse cochlea suggested that FoxM1
may modulate the nuclear targeting of p27Kip1. The relative
expression levels of FoxM1 remained high during development and
decreased at postnatal stages in the Igf12/2 with respect to the
Igf1+/+cochlea (Fig. 5C). At P15, FoxM1 protein was located in
both genotypes at the stria vascularis, the auditory ganglia and in
the organ of Corti (Fig. 5D–M).
To further identify common transcriptional regulators of the
IGF-I cochlear target genes, the 59UTR promoter regions (1.5 kb
upstream) of the selected genes were searched using MEME
software. Those with the lowest p-value for random recurrence
were selected and were analysed with TESS. Finally, the consensus
sequences with the highest probability of matching motifs were
selected. From two different analyses of genes up-regulated in the
Igf12/2 cochlea a possible binding site for the MEF2 transcription
factor was identified with the strongest likelihood of alignment.
There are four members of the MEF2 family of transcription
factors, A to D, whose tissue expression and functions are not well
known [44]. MEF2A and D are expressed in neuronal progenitors
and specific neuronal populations and Mef2c2/2 mice show
aberrant neuronal migration during development and immature
adult neurons [45]. In muscle cells, MEF2 levels are modulated by
IGF-I, which delays MEF2 degradation by the ubiquitin-
dependent proteasome pathway and promotes MEF2 transloca-
tion to the nucleus [46]. Here we study the cochlear expression
and regulation of MEF2 family members by IGF-I (Fig. 6).
Western blot studies showed that the levels and subcellular
location of MEF2 were altered in the Igf12/2 cochlea when
compared to the wild type control (Fig. 6A,B,C). At E18.5,
MEF2A protein levels were 26% lower in the cytoplasm (p,0.05)
and 32% lower (p,0.01) in the nucleus, whereas, at P15 both
cytoplasmic and nuclear levels were 40% lower (p,0.05) (Fig. 6B).
On the other hand, MEF2D protein levels in the E18.5 Igf12/2
cochlea were similar in the cytoplasm but 43% lower (p,0.05) in
the nucleus, while at P15, they were lower in both fractions (25%,
p,0.01, and 19% in the cytoplasm and nuclear fractions,
respectively) (Fig. 6C). Mef2a, Mef2c and Mef2d temporal
expression profiles were studied in the cochlea of Igf1+/+ and
Igf12/2 mice by qRT-PCR from E15.5 to P90 (Fig. 6D). Mef2a
and Mef2d showed similar differences in expression level in
embryonic and adult tissue, being slightly higher in Igf12/2
cochleae at E15.5 and lower at P5 and P90. In contrast, Mef2c
expression levels were much lower at all ages and MEF2C protein
was undetectable. Fig. 7 shows the localization of MEF2A and D
immunostaining in the E18.5 and P15 mouse cochlea of both
genotypes. MEF2A immunostaining was strong in E18.5 auditory
ganglion neurons, although it presented a more diffuse cellular
pattern in immature neurons of Igf12/2 mice (Fig. 7A,B,C). At
P15, MEF2A immunostaining was visible in the auditory ganglion
(Fig. 7I,J,K), pillar cells, Deiter’s cells and inner hair cells
(Fig. 7L,M) of both genotypes. MEF2D expression was observed
in the auditory ganglia and organ of Corti at E18.5
(Fig. 7D,E,F,G,H) and P15 (Fig. 7N,O,P,Q). At E18.5, MEF2D
label was strong and mostly located in the cytoplasm of the hair
cells in the Igf12/2 (Fig. 7H), whereas at P15 immunostaining
decreased in the null mouse (Fig. 7O,Q) and was strongly nuclear
in the neurons and inner hair cells of the wild type cochlea
(Fig. 7N,P).
Discussion
We have studied the molecular mechanisms by which IGF-I
regulates cochlear development and maturation by analyzing the
following parameters in the Igf1+/+ wild type and Igf12/2 null
mouse cochleae: i) the spatiotemporal expression of IGF-system
factors, receptors and binding proteins; ii) the activation of the
main IGF-I signalling kinases Akt, ERK and p38; iii) total cochlear
transcriptome changes caused by IGF-I-deficit by using mRNA
arrays; and iv) transcription factors associated with neuronal cell
cycle regulation modulated by IGF-I availability. We have found
novel regulatory genes for cochlear development whose normal
expression and activation depends on IGF-I. Severe syndromic
deafness in man is associated with null mutations in IGF1 [9,10,11]
and also with low levels of IGF-I [47]. Accordingly, the Igf12/2
mouse shows poor growth rates, high mortality, profound
sensorineural deafness and late postnatal morphological alterations
in the cochlea [16] We have shown previously that the absence of
IGF-I causes poor myelination and delayed maturation of auditory
neurones that suffer apoptosis during the early postnatal mouse
development P5-P20 [17,18]. At birth, however, the Igf12/2
mouse cochlea is the normal size with the expected complement of
cell types in the organ of Corti. At the molecular level, signs of
delayed differentiation were obvious, but the molecular clues
underlying this cochlear-specific phenotype were not clear. Here
we show that IGF-I deficit could be compensated, at least in part,
by increased expression of its high affinity receptor, which can also
be activated by other insulin family factors, whose gene expression
levels were unchanged. Typical IGF-I intracellular target kinases
were also examined in the cochlea, and interestingly a 25%
reduction in the activated forms of prosurvival Akt kinase and
proliferation-associated ERK1/2 were found, with a dramatic
increase in the levels of the stress kinase p38. Further analysis to
uncover IGF-I targets in the cochlea was carried out by using gene
microarrays to do a comparative analysis of the expression profiles
of the developing cochlea in Igf1+/+ and Igf12/2 mice.
Here, we have identified 231 genes that are differentially
expressed in the cochlea of the Igf12/2 mouse. A subset of these
genes was further studied by using a combination of complementary
approaches to further understand IGF-I actions in the inner ear. To
our knowledge, this is the first time that a comparative gene
expression profile has been carried out in an Igf12/2 mouse tissue.
Fig. 8 schematically shows the localization of the differentially
expressed genes in Igf12/2 cochleas that are known to be important
for inner ear development or to be linked to inherited deafness (9%
of total), including Kcnd2, Slc19a2 and Ush1c. The later encodes the
stereociliary protein harmonin and mutations in this gene cause
Usher’s Syndrome 1C [32]. Interestingly, the syndrome includes
retinal degeneration, which is also associated with mutations in Rp1h
[34], a gene expressed at higher levels in the Igf12/2 cochlea. Over-
expression of IGF-I causes profound alterations in the vascularisa-
tion of the mouse eye [48] but to our knowledge there are no reports
of eye defects associated with IGF-I deficiency. In contrast, IGF-I
deficit in the mouse severely impairs normal development of the
olfactory bulb [49]. 91% of the genes we found differentially
expressed in the Igf12/2 cochlea had not been described previously
in the inner ear. For example, Fgf15, the ortholog of human and
chicken Fgf19, presented an expression pattern suggestive of a novel
contribution to cell fate specification within the sensory epithelia.
This raises the question of the specific role of this member of the
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Figure 5. IGF-I deficiency modifies FoxM1 and p27Kip1 levels and intracellular localization. (A) Cytoplasmic and nuclear fractions of
protein extracts obtained from at least 12 different E18.5 or P15 Igf1+/+ or Igf12/2 mouse cochleas in at least six different experiments were
immunoblotted to detect the presence of FoxM1 and p27Kip1. Blots were reprobed with b-actin (cytoplasmic fraction) or histone H3 (nucleus) as
loading controls. The specific bands were measured by densitometry to determine the average expression with ImageJ software. Results were
normalized by assigning a value of 100 to the cytoplasmic Igf1+/+ and represented graphically in (B). (C) Relative quantification value (RQ) of Foxm1
expression in the Igf12/2 cochlea compared to Igf1+/+, estimated by qRT-PCR at E15.5, E18.5-P5 and P15-P90. Data are presented as log10RQ average.
(D–M) Localization of immunostaining for FoxM1 in the P15 Igf1+/+ (D–H) and Igf12/2 (I–M) mouse cochlea. The expression was located in the AG, the
stria vascularis and the organ of Corti (white arrows). Statistical significance estimated with the Student’s t-test was: ***p,0.005; **p,0.01; *p,0.05,
of mutant versus wild type mice data. Open and closed bars: Igf1+/+ and Igf12/2 mice, respectively. Cyt, cytoplasm; Nuc, nucleus; AG, auditory ganglia,
IHC, inner hair cell; OC, organ of Corti; OHC, outer hair cell; SM, scala media. Scale bars: D, 100 mm (D,I); E, 20 mm (E,F,J,K) and G, 20 mm (G, H, L, M).
doi:10.1371/journal.pone.0008699.g005
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FGF family during inner ear development and of its possible
regulation by IGF-I [12].
Several transporters fundamental for the traffic of synaptic
vesicles were also expressed differentially in the Igf12/2 cochlea,
which is consistent with previous observations of aberrant synapsis
at the inner hair cells [17]. For example, the thiamine transporter,
Slc19a2 [32,50], the choline and acetylcholine transporters, Slc5a7
and Slc18a3 [51], and the membrane protein Vamp1 were normally
Figure 6. IGF-I deficiency modifies MEF2 levels and intracellular localization. (A) Cytoplasmic and nuclear fractions of protein extracts
obtained from E18.5 and P15 normal or Igf12/2 mouse cochleae (n = 21, from at least 7 different experiments) were immunoblotted to detect the
presence of MEF2A and MEF2D. Blots were re-probed with b-Actin (cytoplasmic fraction) or histone H3 (nucleus) as loading controls. The specific
bands were measured by densitometry (ImageJ software) to determine the average expression. Results were normalized respect to b-actin or histone,
a value of 100 was assigned to the scanned intensity of cytoplasmic forms in Igf1+/+ and represented graphically in (B,C). (D) Mef2a, Mef2c and Mef2d
expression was measured by qRT-PCR at E15.5, E18.5-P5 and P15-P90 data points in the Igf12/2 mouse cochleas and compared with the Igf1+/+. Data
are presented as the mean of log10RQ. Statistical significance estimated with Student’s t-test was: ***p,0.005; **p,0.01; *p,0.05. Open bars: Igf1
+/+
mouse; Closed bars: Igf12/2 mouse. Cyt, cytoplasm; Nuc, nucleus, b-act, b-actine; H3, histone 3.
doi:10.1371/journal.pone.0008699.g006
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expressed in the inner hair cells of the mouse but their levels were
consistently lower in the Igf12/2 cochlea. In contrast Mlc1, which
encodes a protein located in the afferent fibers of the inner hair
cells [52], was expressed at higher levels. These data support the
idea that IGF-I is a key molecule for the maturation of the
auditory neurons and the refinement of the synaptic connections at
the inner hair cells.
Alterations in ion homeostasis and transport were also
associated with IGF-I deficit because Kcnd2, Kif17, Kcnmb1 and
Cacna1f showed lower levels in Igf12/2 cochleae. Kcnd2 encodes
the K+ channel Kv4.2, which is expressed in neurons that
innervate apical hair cells, which regulates dendritic excitability
[53] and which is transported to the dendrites by the neuronal
kinesin Kif17 [54]. The calcium-activated potassium channel
Kcnmb1 is know to be expressed in the cochlea but the null mouse
has no obvious cochlear phenotype or hearing impairment [55]. In
contrast, the presence of the calcium channel Cacna1f had not been
described previously in the mouse cochlea, but mutations in man
and mouse cause retinal neurotransmission disorders [56,57]. In
addition, differentially regulated genes included Claudin 18 a tight
Figure 7. MEF2A and MEF2D immunolocalization in the cochlea of Igf1+/+ and Igf12/2 mice. MEF2A expression in the cochlea of E18.5
(A,B,C) and P15 (I,J,K,L,M) Igf1+/+ (A,B,I,J) and Igf12/2 (C,K) mice. At E18.5, MEF2A strongly stained the nuclei in the Igf1+/+ auditory ganglion
(arrowheads in B), whereas fewer nuclei appeared labelled in the Igf12/2 ganglia (arrowheads in C) where the staining appeared more cytoplasmatic.
At P15, labelling was similar in the neurones (J,K), Deiter’s cells, pillar cells and in the IHC (L,M) of both genotypes. MEF2D expression at E18.5 was
shown in the auditory ganglia (E,F) and organ of Corti (G,H). MEF2D expression was less nuclear in the Igf12/2 (F, arrowheads pointing to unlabelled
nuclei, H) than in the wild type mouse (E,G). At P15, MEF2D expression was observed in the nuclei of auditory neurons (N) and in the IHC (P,P’) in the
Igf1+/+ but not in the Igf12/2 mouse (O,Q). AG, auditory ganglion; IHC, inner hair cells; OHC, outer hair cells; SM, scale media; ST, scala tympani; SV,
scala vestibule. Scale bars:. A, 100 mm; B, 25 mm (B,C,E,F); D, 75 mm; I, 100 mm; G, 20 mm (G,H); J, 20 mm (J,K); L, 20 mm (L,M); N, 20 mm (N,O); P, 20 mm
(P,P’,Q).
doi:10.1371/journal.pone.0008699.g007
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junction protein expressed in the stria vascularis [2] and the
estrogen related receptor Esrrb, whose mutations in man cause
autosomal-recessive non syndromic hearing impairment and that
is expressed and controls the development of the strial marginal
cells [20,21]. These data taken together suggest that ion
homeostasis and vesicular transport are impaired in the deaf
Igf12/2 mouse.
Neuronal fate specification is mastered by transcription factors
like Six6 and Mash1, which are typically expressed in the central
nervous system. Six6 is a member of the Six/sine oculis family and
it is known to be expressed in the developing and adult retina, in
the optic nerve, and in the hypothalamic and pituitary regions
[58,59]. Mash1 is a proneural transcription factor of the basic
helix-loop-helix family, which participates in the commitment of
neural progenitors, promotion of cell cycle exit and neuronal
migration, and in the final specification of neuronal identities in
the brain [60,61]. Interestingly, both were increased in the Igf12/2
mouse embryonic cochlea, Mash1 transcripts were visible in the
central part of the auditory nerve at the glial transition zone [37],
where Atoh1, another member of the bHLH transcription factor
family [62], has been shown to play a central role in root neurons
survival and on the functional maintenance of the peripheral and
central auditory pathway [63]. Taken together these data suggest
that these bHLH transcription factors are key players for the
differentiation and survival of the neurons at the interface between
the peripheral and central nervous systems.
IGF-I promotes a faster transition of the otic neural progenitors
to a mature neuronal state in the developing chicken inner ear
[12,64]. These data taken together suggest that IGF-I represses the
expression of Six6 and Mash1 during normal inner ear develop-
ment either directly or indirectly to facilitate neuronal differenti-
ation.
It is known that IGF-I is a key factor for cell cycle progression
and DNA repair and several cell types in the Igf12/2 mouse,
including cochlear neurones, are smaller and more immature than
those of the wild type mouse [17,18,65]. Here we show that in the
cochlea, IGF-I deficit causes an increase in IGF1R expression
levels although there is a net reduction in the ratio of tyrosine
phosphorylation, an increase in the activated phospho-p38 stress
kinase, and a decrease in the levels of the active phosphorylated
forms of the kinases ERK1/2 and Akt, the main intracellular
executors of IGF-I actions, indicating that the balance between cell
proliferation, survival and differentiation is altered. However, the
complexity of the regulation of cellular processes was evidenced by
the contrasting increase in the expression levels of the forkhead
transcription factor Foxm1. FoxM1 is essential for mitotic
progression and for the transcriptional response during DNA
damage/checkpoint signalling [42,66,67]. Its presence in the
developing cochlea had not been reported previously. Its increased
activation in the Igf12/2 cochlea was confirmed by its nuclear
localization and by the inhibition of one of its downstream targets,
the cyclin-dependent kinase inhibitor p27Kip1. In contrast,
transcripts for other cell cycle proteins, such as INCENP, were
expressed at lower levels, suggesting problems in chromosome
segregation [68]. In early postnatal cochleae from Igf12/2 mice
there is increased neuronal apoptosis and delayed neuronal
maturation, but there is no evidence for altered cellular
proliferation or cell damage [17]. These data suggest that FoxM1
Figure 8. Differentially expressed genes in the IGF-I-deficient cochlea. Names of selected differentially expressed genes (red) are shown on a
schematic drawing of the adult scala media. BC, border cells; BsC, basal cells; BM, basilar membrane; CC, Claudius’s cells; DC, Deiter’s cells; HC,
Hensen’s cells; IC, intermediate cells; IDC, interdental cells; IHC, inner hair cells; IPC, inner phalangeal cells; IS, inner sulcus; Li, spiral limbus; MC,
marginal cells; OHC, outer hair cells; PC, pillar cells; RM, Reisner’s membrane; AG, auditory ganglion; SL, spiral ligament; SM, scala media; ST, scala
tympani; SV, scala vestibuli; TM, tectorial membrane.
doi:10.1371/journal.pone.0008699.g008
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activation compensates for the unbalanced progression through
the cell cycle caused by IGF-I deficit.
Further insight into IGF-I cochlear targets was obtained by in
silico analysis of the promoters of IGF-I-modulated genes that
unveiled a potential role for MEF2 and its modulation by IGF-I in
the cochlea. MEF2 is essential for myogenic and neuronal
differentiation [45,69]. In both cell types, IGF-I activates MEF2
by decreasing its degradation rate and by preventing its
translocation from the nuclei to the cytoplasm [46,69]. MEF2D
is expressed in sensory neurons during development and it is
regulated by a TrkA-dependent ERK5 pathway that promotes
neuronal survival [70]. MEF2 is activated by the Raf/MAPK
cascade [46] and also by p38 MAPK [71]. Here we show that
MEF2A and D but not C are highly expressed in the nuclei of
embryonic mouse auditory ganglion neurons and that nuclear
MEF2 protein levels are lower in the developing Igf12/2 cochlea.
These data reinforce the conclusion that MEF2A and D are key
targets for otic IGF-I action and that they may have a fundamental
role during cochlear development. To our knowledge, this is the
first time that MEF2 transcription factors expression has been
reported in the auditory ganglia.
In summary, we show that Igf1 and Igf1r are expressed in the
developing mouse cochlea with complementary cellular patterns.
The stria vascularis apparently provides an intra-cochlear source
of IGF-I. Analysis of IGF-I-deficient cochlea showed that the
signalling levels of Akt and ERK1/2 were lower and that p38
activation was significantly higher. Transcriptional profiling of the
Igf12/2 cochlea identified potential novel IGF-I targets, including
factors like Six6, Mash1 and Fgf15. Finally, the transcription factors
FoxM1, Mef2a and Mef2d are expressed in the developing inner ear
and their sub-cellular localisation is modulated by IGF-I
availability. The results presented here offer new insight into the
mechanisms by which IGF-I support sensory cell and neuronal
survival and differentiation in the auditory receptor, and reveal
novel regulatory mechanisms of the cell cycle during cochlear
development.
Supporting Information
Figure S1 Spatiotemporal expression patterns of Igf1r mRNA
and IGF1R protein in the Igf1+/+and Igf12/2 mouse cochlea. (A–
F) shows that the mRNA expression of Igf1r was identical in the
two genotypes. (A,B,C) P5 Igf1+/+ and (D,E,F) P5 Igf12/2 mice.
IGF1R protein was shown at the organ of Corti and in the
auditory ganglion at E15.5 (G,H) and E18.5 (I,I’,J,J’) with similar
cellular localization between genotypes. At P15, the expression was
located mainly in the neurons of the auditory ganglion (K,L), no
differences could be observed. AG, auditory ganglion; BsC, basal
cells IHC, inner hair cells; MC, marginal cells; OC, organ of
Corti; OHC, outer hair cells; SM, scale media; ST, scala tympani;
SV, scala vestibule, TM, tectorial membrane. Scale bars: A,
150 mm (A,D); B, 20 mm (B,C,E,F); G, 20 mm (G,H); I, 100 mm
(I,J); I’, 20 mm (I’,J’); K, 20 mm (K,L).
Found at: doi:10.1371/journal.pone.0008699.s001 (3.53 MB
DOC)
Figure S2 IGF-I deficiency modifies IGF1R phosphorylation
levels.Protein extracts obtained from E15.5, E18.5, P5, P60 and
P90 Igf1+/+ or Igf12/2 mouse cochleas (n = 6, from at least 2
different experiments) were immunoblotted to detect the presence
of pIGF1R. Blots were re-probed with IGF1R as loading control.
The specific bands were measured by densitometry (ImageJ
software) to determine the average expression. Results were
normalized, a value of 100 was assigned to the scanned intensity of
the E15.5 Igf1+/+ cochlear extract. Statistical significance estimat-
ed with Student’s t-test was: **p,0.01; *p,0.05. Open bars:
Igf1+/+ mouse; Closed bars: Igf12/2 mouse.
Found at: doi:10.1371/journal.pone.0008699.s002 (0.05 MB TIF)
Figure S3 Clustering of the differentially expressed genes in
Igf12/2 cochleas grouped according to their functional category.
The 231 genes differentially expressed (closed bars), were classified
by their biological annotation compared with all Mus musculus
genome annotations in the NCBI (open bars). The statistical
analysis of the biological processes included a Bonferroni
correction for multiple testing and processes were selected at
p,0.05. The differentially expressed genes are implicated in the
following biological processes: signal transduction, developmental
process, ligand-mediated signalling, cell communication, immuni-
ty and defence, cytokine and chemokine mediated signalling,
muscle contraction, lipid, fatty acid and steroid metabolism,
granulocyte-mediated immunity and homeostasis.
Found at: doi:10.1371/journal.pone.0008699.s003 (0.20 MB TIF)
Figure S4 Mash1 expression in the Igf1+/+and Igf12/2 P5 mouse
auditory nerve.(A–K) Mash1 in situ hybridization was performed
on cryostat sections in Igf1+/+ (A–G) and Igf12/2 (H–K) cochleas
at P5. Axons in the auditory nerve (AN) were recognised by 3A10
immunostaining (red C,D,F,G,J,K). At P5,Mash1 expression in the
auditory nerve did not show differences between genotypes (B–
G,I–K). B, E and I are higher magnification images of the boxed
areas in A and H, respectively. D,G,K are merge images of Mash1
and 3A10 labelling. (L–S) Double in situ hybridization of Mash1
(red; L,P,O,S) and inmunohistochemistry of myelin basic protein
(green, MBP; M,Q,O,S). Cell nuclei were stained with DAPI (blue;
N,R,O,S). Mash1 expression was perinuclear and was associated at
P5 to the soma of cells, probably root neurones, embedded in
auditory axons (white arrows; L–S). Three embryos per genotype
were tested in parallel in three independent experiments. AN,
auditory nerve; SM, scala media; ST, scala tympani; SV, scala
vestibuli. Scale bars: H, 150 mm (A, H); K, 30 mm (B–G,I–K), L,
35 mm (L–O); P, 20 mm (P–S).
Found at: doi:10.1371/journal.pone.0008699.s004 (7.24 MB TIF)
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